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Abstract
Background: Antiangiogenic therapy is one of the most significant advances in anticancer treatment. The benefits
of antiangiogenic therapies of late-stage cancers have been investigated but are still too limited.
Methods: We used an ovarian cancer model to test the effect of short-term bevacizumab treatment on metastasis
as measured by bioluminescence. Western blotting and CD34-PAS dual staining were performed to assess hypoxia-
inducible transcription factor-1a (HIF-1a) expression and vasculogenic mimicry(VM) formation. Cell viability was
examined by a CCK8 assay.
Results: Bevacizumab demonstrated antitumor effects in models of ovarian cancer, but also accelerated metastasis
together, with marked hypoxia and VM formation in mice receiving short-term therapy. Bevacizumab treatment did
not affect SKOV3 cell viability and the amount of VM in three-dimensional culture.
Conclusion: These results suggest that antiangiogenic therapy may potentially influence the progression of
metastatic disease, which has been linked to the hypoxic response and VM formation.
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Background
Tumors can grow to a maximum diameter of between 1
and 2 mm before their metabolic demands are restricted
due to the diffusion limit of oxygen and lack of essential
nutrients. To exceed this size or spread to other organs,
tumors require an independent blood supply. In the
1970s, Folkman et al was the first to propose the con-
cept of antiangiogenesis as a therapeutic approach to
treat solid tumors [1]. Targeting the blood supply by
inhibiting the formation of b l o o dv e s s e lw i l ll e a dt o
tumor growth arrest. Numerous angiogenesis inhibitors
have been therapeutically used in both preclinical and
clinical settings [2]. Vascular endothelial growth factor
(VEGF) receptor tyrosine kinase inhibitors and a VEGF-
neutralizing antibody have been clinically validated to
target VEGF or its receptors as an anticancer treatment.
However, a number of limitations are observed in cur-
rent antiangiogenic therapies. Many clinical benefits are
short-lived, and enduring clinical responses are rare.
While numerous trials have shown an increase in survi-
val after patients are treated with antiangiogenic therapy,
t h ei n c r e a s ef o rm a n yw a so n l yam a t t e ro fm o n t h s[ 3 ] .
Moreover, single-agent use of antiangiogenesis appears
to be insufficient to improve patient survival [4]. While
any improvement in overall survival for patients should
be regarded as advancement, it is importart to under-
stand why such clinical improvements are sometimes
transitory so that new therapies result in more enduring
benefits.
One explanation for these limitations is a potential
link between antiangiogenic therapy and increased
metastasis [5]. In RIP-Tag2 mice treated with the VEGF
receptor 2-inhibitor DC101, although tumors were smal-
ler, they showed significantly more invasive and malig-
nant phenotypes, with most showing wide fronts of
invasion into urrounding acinar tissues [6]. Rodents
treated with an anti-VEGF antibody showing a striking
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any medium, provided the original work is properly cited.increase in the number and total area of small satellite
tumors compared with those that had not received anti-
angiogenic therapy, and tumor cells often had migrated
over long distances [7,8]. Together, these results suggest
that antiangiogenic therapy may influence the progres-
sion of metastatic disease. To understand the reasons
for these observations and to enable enduring benefits
of antiangiogenic therapies, we examined the effect of a
VEGF-neutralizing antibody on metastasis in mice after
short-term administration. Furthermore, the hypoxic
response and vasculogenic mimicry (VM) formation
were assessed in this study.
Materials
Antibodies
For western blotting and histopathological analyses, a
mouse anti-HIF-1a monoclonal antibody was purchased
from Novus Biologicals (Littleton, CO, USA), CD34
monoclonal antibody from Abgent (San Diego, CA,
USA).
Cell lines
The human ovarian cancer cell line SKOV3 was pur-
chased from the ATCC and transfected with a lucifer-
ase-expressing lentivirus containing an independent
open-reading frame of GFP. After 72 hours, cells were
examined by fluorescence microscopy to confirm infec-
tion. Luciferase expression was determined using luci-
ferin and an in vivo imaging system (Xenogen). Cells
were maintained in RPMI-1640 medium supplemented
with 10% heatinactivated fetal bovine serum (Gibco Invi-
trogen Corp), and incubated at 37°C in a humidified
atmosphere containing 5% CO2.
Three-dimensional(3D) cultures
Matrigel (BD Biosciences) was placed dropwise onto
glass coverslips in 12-well culture plates and allowed to
polymerize for 30 min at 37°C. SKOV3 cells were then
seeded onto the 3D matrix in complete medium.
Animal models
SKOV3
LUC+ cells (1.2 × 10
6 cells) were directly injected
into the tail vein of 6- 8-week-old female nude mice.
Forty mice were assigned into four groups(A, B, C and
D). Group A was treated with phosphate-buffered saline
(PBS) bi-weekly for 3 weeks. Group B was treated with
40 mg/kg bevacizumab bi-weekly for 3 weeks. Group C
was treated with 3 mg/kg cisplatin weekly for 3 weeks.
Group D was treated with both bevacizumab bi-weekly
and cisplatin weekly for 3 weeks. Bevacizumab and cis-
platin were administered intraperitoneally. Body weight
was measured and recorded weekly. Metastatic disease
progression in SKOV3
LUC+ tumor-bearing mice was
monitored. Before mice were anesthetized with Forane,
an aqueous solution of luciferin (150 mg/kg) was intra-
peritoneally injected at 10 min prior to imaging. Mice
were placed into the light-tight chamber of a CCD cam-
era system (Xenogen), and photons emitted from luci-
ferase-expressing cells within mice were quantified for 1
min, using the software program living. Four weeks after
initial treatment, all mice were sacrificed to assess the
effects of drug treatments. All procedures involving
mice complied with the Guide for the Care and Use of
Laboratory Animals (National Institutes of Health).
Western blotting
The tissues were homogenized in 0.5 ml Hepes (50 mM,
pH 7.5) containing 100 mM NaCl, 1 mM CaCl2,1m M
dithiothreitol, 1% ethylene glycol-bis(aminoethyl ether)-
tetraacetic acid 1% Triton X- 100 and proteinase inhibi-
tors. Protein extracts were kept in ice for 30 min and
then centrifuged at 14,000 g at 4°C for 30 min. Protein
concentrations were determined using a bicinchoninic
acid protein assay reagent kit. Protein samples (20 mg)
were mixed with equal volumes of loading buffer (20%
glycerol, 4% sodium dodecyl sulfate, and 100 mM Tris-
HCl, pH 6.8) and then boiled for 5 min in the presence
of b-mercaptoethanol. Proteins were separated in 8%
sodium dodecyl sulfate-polyacrylamide gels at 100 V for
2 h and then electrotransferred to nitrocellulose mem-
branes at 270 mA for 2 h. Membranes were blocked with
5% non-fat dry milk in PBS with 0.1% Tween 20 for 1 h
at room temperature. Then, membranes were incubated
with anti- HIF-1a (1:500) overnight at 4°C and finally
with a horseradish peroxidase-conjugated anti-mouse
IgG for 1 h at room temperature after washing with TBS
containing 0.1% Tween 20. Proteins were visualized by
enhanced chemiluminescence reagents after washing.
Protein expression was semi-quantified using an image
analysis system.
CD34-PAS dual staining
Four micrometer paraffin sections were routinely deparaf-
finized and dehydrated. First, CD34 immunohistochemical
staining was applied to the sections. Endogenous peroxi-
dase activity was blocked with 3% hydrogen peroxide in
50% methanol for 10 min at room temperature. Sections
were rehydrated and washed with PBS and then pretreated
with citrate buffer (0.01 M citric acid, pH 6.0) for 20 min
at 100°C in a microwave oven. Non-specific binding sites
were blocked with 2% normal goat serum in PBS for 20
min at 37°C. Sections were then incubated overnight at 4°
C with anti-CD34 at a 1:200 dilution. Then, sections were
rinsed with PBS and incubated with biotinylated goat anti-
mouse IgG for 20 min at 37°C, followed by incubation
with 3,3’-diaminobenzidine(DAB) chromogen for 10 min
at room temperature. Sections were then rinsed with
water for 1 min to stop the DAB-staining reaction.
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the methods mentioned above. Finally, sections were trea-
ted with 0.5% periodic acid solution for 10 min and rinsed
with distilled water for 2-3 min. In a dark chamber, sec-
tions were treated with Schiff solution for 15-30 min.
After rinsing with distilled water, sections were counter-
stained with hematoxylin [9].
Cell counting kit 8 (CCK8) assay
Cell viability was measured by conversion of Dojindo’s
highly water-soluble tetrazolium salt WST-8 to a yellow-
colored watersoluble formazan (CCK8 assay). The amount
of formazan dye generated by the activity of mitochondrial
dehydrogenases in cells is directly proportional to the
number of living cells. CCK8 is more sensitive than the 3-
(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bro-
mide assay [10]. SKOV3 cells were trypsinized and seeded
at 5 × 10
3 cells/well in 96 well plates in 3D cultures. After
24 h, various concentrations of bevacizumab were added,
followed by incubation for another 48 h. Then, 10 μL
CCK8 (Sigma, USA) solution in PBS was added to each
well. Plates were incubated for an additional 2 h. The opti-
cal density of each well was measured using a microcul-
ture plate reader at a 490 nm wavelength.
Statistical analysis
All results were evaluated using the SPSS 13.0 statistical
software package. Data were analyzed using one-way
ANOVA. Results were expressed as the mean ± stan-
dard deviation, and P < 0.05 was considered statistically
significant.
Results
Increased metastasis after short-term treatment with the
angiogenesis Inhibitor bevacizumab
In our study, a model of metastasis was used to test the
effect of short-term bevacizumab treatment. SKOV3
LUC+
cells expressing luciferase were directly injected into the
tail vein of female nude mice and then received bevacizu-
mab and/or cisplatin treatment for 3 weeks. Forty mice
w e r ee q u a l l yd i v i d e di n t of o u rg r o u p sa tr a n d o m( P B S ,
bevacizumab, cisplatin and bevacizumab + cisplatin
groups). Tumor growth and metastasis were monitored by
bioluminescence at 1 and 4 weeks after treatment. Mean
photon counts of each group were quantified, and the
ratio of metastasis was measured. The pulmonary metasta-
sis rate was 100%. Tumor growth delay was observed at 1
week after bevacizumab and/or cisplatin treatments, with-
out extrapulmonary metastasis. Short-term bevacizumab
treatment resulted in accelerated extrapulmonary metasta-
sis at 4 weeks after treatment. Extrapulmonary metastases
were found in livers and legs. Cisplatin and bevacizumab +
cisplatin treatment inhibited tumor growth, compared
with that of PBS treatment.. While no significant differ-
ence in tumor growth was observed between bevacizumab
and control groups (Figure 1).
Hypoxia is implicated in the adaptive response
To gain an insight into possible molecular mechanisms
of the increased metastasis, we determined whether
hypoxia development was concomitant with metastasis.
Mice were assigned into four groups (PBS, bevacizumab,
cisplatin and bevacizumab + cisplatin) and received bev-
acizumab and/or cisplatin treatments for 3 weeks. Four
weeks after initial treatment, five mice from each group
were sacrificed for examination. Expression of HIF-1a
in pulmonary tumor nodules was analyzed by western
blotting. In PBS and cisplatin groups, most tumors
showed little hypoxia. In contrast, mice that received
bevacizumab and bevacizumab + cisplatin therapy
showed a markedly increased level of HIF-1a expression
(Figure 2). Differences in HIF-1a protein levels in each
group were considered statistically significant.
Figure 1 Increased metastasis after short-term treatment with
bevacizumab. Forty mice were assigned into four groups (PBS,
bevacizumab, cisplatin and bevacizumab + cisplatin). Mean photon
counts of each group were quantified. (A) Tumor growth and
metastasis were monitored by bioluminescence at 1 and 4 weeks
after treatment. A representative experiment is shown. (B) Short-
term bevacizumab treatment resulted in accelerated extrapulmonary
metastasis at 4 weeks after treatment. Extrapulmonary metastases
were found in the livers and legs. The ratio of metastasis of each
group was measured. (C) Quantification of bioluminescence showed
inhibited tumor growth in bevacizumab and/or cisplatin treatment
groups at 1 week after treatment, compared with that of the PBS
group. Bevacizumab + cisplatin treatment inhibited tumor growth,
compared with that of cisplatin at 1 week after treatment. (D)
Quantification of bioluminescence showed no significant difference
in tumor growth between bevacizumab and PBS groups 4 weeks
after treatment. Bevacizumab + cisplatin treatment inhibited tumor
growth compared with that of cisplatin at 4 weeks after treatment.
*P < 0.05, **P < 0.01.
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The definition of VM is that tumor cells mimic
endothelial cells and form vasculogenic networks.
CD34-PAS double staining was used to distinguish VM
and endothelial-dependent vessels. CD34 is a marker of
endothelial cells, and the basement membrane is posi-
tive for PAS. Therefore, we counted PAS-positive and
CD34-negative vessels for indicate. Mice were assigned
into four groups (PBS, bevacizumab, cisplatin and beva-
cizumab + cisplatin) that received bevacizumab and/or
cisplatin treatments for 3 weeks. Four weeks after initial
treatment, five mice from each group were sacrificed for
examination. Tumors in the bevacizumab group formed
more VM channels than those of PBS and cisplatin, and
bevacizumab + cisplatin groups (Figure 3).
In vitro experiment demonstrating the effect of
bevacizumab on VM
SKOV3 cells were cultured in 3D culture, which formed
VM channels. Then, we compared the cell viability and
the ability to form VM in 3D culture after treatment
with bevacizumab (0, 1, 10, 100 and 1000 μg/ml)for up
to 48 h. Cell viability was examined by a CCK8 assay.
Bevacizumab treatment did not affect SKOV3 cell viabi-
lity and the number of tubules (Figures 4 and 5).
Discussion
Antiangiogenic therapy is one of the most significant
advances in cancer treatment. Its clinical value has been
investigated, but is still too limited. A number of recent
clinical and preclinical observations have been reported.
Figure 2 Hypoxia is implicated in the adaptive response after
short-term bevacizumab treatment. Expression of HIF-1a in
pulmonary tumor nodules of the four groups. (A) A representative
western blot is shown. b-actin was used as a loading control. (B)
While most tumors showed little expression of HIF-1a protein in
PBS and cisplatin groups, mice that received bevacizumab and
bevacizumab + cisplatin therapy showed a markedly increased level
of HIF-1a expression.. *P < 0.05, **P < 0.01.
Figure 3 Anti-VEGF treatment induces increased VM.
Comparison of VM channels in mice with various treatments. VM
channels were positive for PAS staining and negative for CD34
staining in sections (arrow, ×400). (A) PBS (B) bevacizumab (C)
cisplatinp and(D) bevacizumab + cisplatin groups. (E) Comparison of
VM channels in A, B, C and D. Tumors in the bevacizumab group
formed more VM channels than that of PBS and cisplatin, and
bevacizumab + cisplatin groups. **P < 0.01.
Figure 4 Bevacizumab treatment did not affect SKOV3 cell
viability. Bevacizumab treatment (0, 1, 10, 100 and 1000 μg/ml)
does not affect SKOV3 cell viability in 3D culture. There were no
statistically significant difference (P > 0.05).
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ovarian cancer patients treated with the combinational
therapy of carboplatin/paclitaxel with the angiogenesis
inhibitor sorafenib, Pölcher M et al. reported that pro-
gressive disease was diagnosed in two patients out of
four, and surgical exploration showed an increased
number of peritoneal tumor implants [11]. Furthermore,
after short-term treatment, varous forms of antiangio-
genic therapy can lead to increased metastasis in mouse
models of multiple tumor types [12,13]. Thus, there is a
strong need to improve treatment strategies and to bet-
ter understand the mechanisms of failure that hinder
targeted antiangiogenic therapies. Here, we address the
effect of short-term bevacizumab treatment using ovar-
ian cancer xenografts. The data show that short-term
bevacizumab treatment induces a reduction in tumor
growth and an increase in distant tumor metastasis as
measured by bioluminescence. Importantly, similar
results were obtained when nu/nu mice were treated
with bevacizumab + cisplatin and cisplatin alone. It
should be noted that in mouse models of ovarian can-
cer, antiangiogenic therapy can elicit an adaptive
response involving increased dissemination and the
emergence of distant metastasis.
To investigate this metastatic “conditioning” effect, a
better understanding of the biological effects of anti-
VEGF treatment is required. Antiangiogenic therapy
inhibits the development of new blood vessels, i.e.
angiogenesis, resulting in reduced perfusion and an
increase in intratumoral hypoxia, which may indirectly
affect the tumor cells by inducing a more invasive phe-
notype in response to hypoxia, leading to increased
invasion and metastatic dissemination [14,15]. HIF-1a is
a main regulator of the transcriptional response of can-
cer cells to hypoxia. By analyzing HIF-1a expression
using western blotting we showed that treatment with
bevacizumab increases intratumoral hypoxia in metasta-
sis models of ovarian cancer. While most tumors
showed little or no expression of HIF-1a protein in
groups without bevacizumab treatment, HIF-1a expres-
sion markedly increased both in bevacizumab and beva-
cizumab + cisplatin groups. In summary, short-term
bevacizumab treatment results in increased of HIF-1a
expression. Interestingly, HIF-1a regulates genes that
are involved in angiogenesis, cell survival, invasion and
metastasis [16]. Therefore, downstream pathways of
HIF-1a gene may contribute to metastatic phenotypes.
Current antiangiogenic strategies are mainly directed
against tumor endothelial cells. However, tumours do
not only rely on host blood vessels for nourishment,
they can also form their own vasculature. The term
“VM” has been used to describe the manner in which
tumor cells mimic endothelial cells to form vasculogenic
networks. VM has been described in ovarian cancer and
some other highly aggressive tumors such as melanoma,
prostatic carcinoma, breast cancer, soft tissue sarcomas
and lung cancer [17-22]. The presence of VM correlates
to an increased risk of metastasis and poor clinical out-
come [23-26]. Several key molecules, including VE-cad-
herin, matrix metalloproteinases, laminin-5 g2 chain and
EphA2, have been implicated in VM. Moreover, the
tumor microenvironment, including hypoxia, ischemia
and acidosis, plays a major role in trans-endothelial dif-
ferentiation of aggressive tumor cells [27-30]. In the
hypoxic microenvironment, melanoma cells increase
HIF-1a expression and induce the formation of VM
channels to acquire an adequate blood supply [31]. In
3D culture, bevacizumab treatment for up to 48 h did
not affect SKOV3 cell viability and the ability to form
VM. Moreover, our data showed more VM channels in
short-term bevacizumab treatment groups than those in
control groups. This feature suggests that VM channels,
which cannot be inhibited by bevacizumab, may satisfy
the vascular requirements of ovarian cancer growth,
invasion and metastasis during hypoxia. Thus, the
increased of VM formation as a result of bevacizumab-
induced hypoxia may increase dissemination and the
emergence of distant metastasis. These findings offer a
possible explanation for why antiangiogenesis only
shows transitory clinical benefits.
Conclusions
VEGF inhibition causes hypoxia, induces HIF-1a expres-
sion and the formation of VM, which may be associated
Figure 5 Bevacizumab treatment did not affect the number of
tubules. The effect of bevacizumab (0, 10 and 1000 μg/ml) on the
formation of VM channels (× 100). (A) Bevacizumab at 0/(B) 10/(C)
1000 μg/ml. (D) Bevacizumab treatment did not affect the number
of tubules (P > 0.05).
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inhibits endothelium-dependent vessels, and then causes
hypoxia in tumors. To compensate for tumor hypoxia,
VM may increase to maintain the tumor blood supply
and provide a convenient route for tumor metastasis.
Another question raised by our results is whether other
mechanisms linked to the hypoxic response could con-
tribute to the metastatic phenotype, such as angiogen-
esis, growth factor signaling and apoptosis. The
relationship between antiangiogenic therapy and metas-
tasis remains to be determined and is an important
topic for future research. Further study may provide
additional drug targets, resulting in adjuvant therapies
that can enhance the clinical benefits of antiangiogenic
treatment.
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